[A randomized, multicenter, active-controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with that of elcatonin in postmenopausal women with osteoporosis in China].

Zhang XZ, Song LG, Wang B, Yang J, Li H, Xuan M, Lei T, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH and 6 more

Show all authors

Shen J, Liu ZM, Li CJ, Wu TF, Xie HB, Tong JC

Zhonghua nei ke za zhi1 Aug 2010Cited by 1 (Europe PMC)

PMID20979784PepBankPUB-20979784

Publisher pageAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, rhPTH improved lumbar spine BMD more than elcatonin at 3 months.
In plain wordsIn women with osteoporosis, rhPTH improved lower spine bone density more than elcatonin at 3 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD at 3 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
Moreover, the rhPTH (1-34) group had better improvement in L1-4 BMD than the elcatonin group at 3, 6 months, but there was no difference of BMD in these two groups with regard to femoral neck.
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2097978403
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, rhPTH improved lumbar spine BMD more than elcatonin at 6 months.
In plain wordsIn women with osteoporosis, rhPTH improved lower spine bone density more than elcatonin at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD at 6 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
Moreover, the rhPTH (1-34) group had better improvement in L1-4 BMD than the elcatonin group at 3, 6 months, but there was no difference of BMD in these two groups with regard to femoral neck.
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2097978404
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, femoral neck BMD did not differ between rhPTH and elcatonin.
In plain wordsIn women with osteoporosis, femoral neck bone density did not differ between rhPTH and elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD between groups
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
Moreover, the rhPTH (1-34) group had better improvement in L1-4 BMD than the elcatonin group at 3, 6 months, but there was no difference of BMD in these two groups with regard to femoral neck.
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2097978405
04HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, BSAP increased more with rhPTH than elcatonin at 3 months, 36.79% versus 0.31%.
In plain wordsIn women with osteoporosis, rhPTH increased the bone marker BSAP more than elcatonin at 3 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBSAP at 3 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 6 monthsAs given in this study (human).
Measurements
Change in serum BSAP at 3 months
36.79%
rhPTH (1-34) group
Change in serum BSAP at 3 months
0.31%
Elcatonin group
Source sentences
Summary
There were greater mean increases of the bone markers in the rhPTH (1-34) group than those in the elcatonin group at 3, 6 months [serum bone-specific alkaline phosphatase (BSAP) 36.79% vs 0.31%; 92.42% vs -0.17%; the ratio of urine N-telopeptide of type I collagen and creatinine (NTX/Cr) 48.91% vs -…
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2097978406
05HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, BSAP increased more with rhPTH than elcatonin at 6 months, 92.42% versus -0.17%.
In plain wordsIn women with osteoporosis, rhPTH increased the bone marker BSAP more than elcatonin at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBSAP at 6 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 6 monthsAs given in this study (human).
Measurements
Change in serum BSAP at 6 months
92.42%
rhPTH (1-34) group
Change in serum BSAP at 6 months
−0.17%
Elcatonin group
Source sentences
Summary
There were greater mean increases of the bone markers in the rhPTH (1-34) group than those in the elcatonin group at 3, 6 months [serum bone-specific alkaline phosphatase (BSAP) 36.79% vs 0.31%; 92.42% vs -0.17%; the ratio of urine N-telopeptide of type I collagen and creatinine (NTX/Cr) 48.91% vs -…
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2097978407
06HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, NTX/Cr increased more with rhPTH than elcatonin at 3 months, 48.91% versus -5.32%.
In plain wordsIn women with osteoporosis, rhPTH increased the bone marker NTX/Cr more than elcatonin at 3 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseNTX/Cr at 3 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 6 monthsAs given in this study (human).
Measurements
Change in urine NTX/Cr at 3 months
48.91%
rhPTH (1-34) group
Change in urine NTX/Cr at 3 months
−5.32%
Elcatonin group
Source sentences
Summary
There were greater mean increases of the bone markers in the rhPTH (1-34) group than those in the elcatonin group at 3, 6 months [serum bone-specific alkaline phosphatase (BSAP) 36.79% vs 0.31%; 92.42% vs -0.17%; the ratio of urine N-telopeptide of type I collagen and creatinine (NTX/Cr) 48.91% vs -…
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2097978408
07HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, NTX/Cr increased more with rhPTH than elcatonin at 6 months, 68.82% versus -10.86%.
In plain wordsIn women with osteoporosis, rhPTH increased the bone marker NTX/Cr more than elcatonin at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseNTX/Cr at 6 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · 6 monthsAs given in this study (human).
Measurements
Change in urine NTX/Cr at 6 months
68.82%
rhPTH (1-34) group
Change in urine NTX/Cr at 6 months
−10.86%
Elcatonin group
Source sentences
Summary
There were greater mean increases of the bone markers in the rhPTH (1-34) group than those in the elcatonin group at 3, 6 months [serum bone-specific alkaline phosphatase (BSAP) 36.79% vs 0.31%; 92.42% vs -0.17%; the ratio of urine N-telopeptide of type I collagen and creatinine (NTX/Cr) 48.91% vs -…
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2097978409
08HumanRandomized controlled trialSafety outcome
In women with osteoporosis, adverse event rates did not differ between rhPTH and elcatonin.
In plain wordsIn women with osteoporosis, adverse event rates did not differ between rhPTH and elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAdverse event rates
Study
n = 205
Comparator
Elcatonin
Outcome group
Adverse events · Whole body
Studied dose
20 µg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
Both kinds of treatment were well tolerated and there were no differences between the two groups in the rates of adverse events and serious adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2097978410
09HumanRandomized controlled trialSafety outcome
In women with osteoporosis, serious adverse event rates did not differ between rhPTH and elcatonin.
In plain wordsIn women with osteoporosis, serious adverse event rates did not differ between rhPTH and elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerious adverse event rates
Study
n = 205
Comparator
Elcatonin
Outcome group
Adverse events · Whole body
Studied dose
20 µg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
Both kinds of treatment were well tolerated and there were no differences between the two groups in the rates of adverse events and serious adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2097978411

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, lumbar spine (L1-4) BMD rose from baseline in both groups, by 5.51% with rhPTH (1-34) and by 1.55% with elcatonin.
In plain wordsIn women with osteoporosis, lower spine bone density rose from baseline in both the rhPTH and elcatonin groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD change
Study
n = 205
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
L1-4 BMD change from baseline to endpoint
5.51%
rhPTH (1-34) group
L1-4 BMD change from baseline to endpoint
1.55%
Elcatonin group
Source sentences
Summary
From baseline to endpoint, BMD of L1-4 and femoral neck in the rhPTH (1-34) group increased by 5.51% (P0.05), but BMD of L1-4 and femoral neck in elcatonin group increased by 1.55% (P0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2097978401
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, femoral neck BMD did not change significantly from baseline in either the rhPTH (1-34) group (+0.65%) or the elcatonin group (+0.11%).
In plain wordsIn women with osteoporosis, femoral neck bone density did not change significantly from baseline in either the rhPTH or the elcatonin group.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD change
Study
n = 205
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD change from baseline to endpoint
0.65%
rhPTH (1-34) group
Femoral neck BMD change from baseline to endpoint
0.11%
Elcatonin group
Source sentences
Summary
From baseline to endpoint, BMD of L1-4 and femoral neck in the rhPTH (1-34) group increased by 5.51% (P0.05), but BMD of L1-4 and femoral neck in elcatonin group increased by 1.55% (P0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This 6 month, multicenter, randomized and controlled study enrolled 205 postmenopausal women with osteoporosis.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 µg (200 U) daily or elcatonin 20 U weekly.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2097978402

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.